These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38573968)

  • 1. Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
    Stauffer WT; Bobardt M; Ure DR; Foster RT; Gallay P
    PLoS One; 2024; 19(4):e0301711. PubMed ID: 38573968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
    Stauffer WT; Goodman AZ; Bobardt M; Ure DR; Foster RT; Gallay P
    PLoS One; 2024; 19(3):e0298211. PubMed ID: 38427624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
    Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
    Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.
    Motiño O; Li S; Lambertucci F; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Chen H; Maiuri MC; Kroemer G; Martins I
    Methods Mol Biol; 2024; 2769():67-75. PubMed ID: 38315389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
    Kuo J; Bobardt M; Chatterji U; Mayo PR; Trepanier DJ; Foster RT; Gallay P; Ure DR
    J Pharmacol Exp Ther; 2019 Nov; 371(2):231-241. PubMed ID: 31406003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophilin D induces necrotic core formation by mediating mitochondria-associated macrophage death in advanced atherosclerotic lesions.
    Koga JI; Umezu R; Kondo Y; Shirouzu T; Orkhonselenge N; Ueno H; Katsuki S; Matoba T; Nishimura Y; Kataoka M
    Atherosclerosis; 2024 Sep; 396():118524. PubMed ID: 38972156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.
    Kuo J; Serrano SS; Grönberg A; Massoumi R; Hansson MJ; Gallay P
    Front Pharmacol; 2019; 10():1129. PubMed ID: 31611801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
    Simón Serrano S; Grönberg A; Longato L; Rombouts K; Kuo J; Gregory M; Moss S; Elmér E; Mazza G; Gallay P; Pinzani M; Hansson MJ; Massoumi R
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
    J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-specificity phosphatase 3 deletion promotes obesity, non-alcoholic steatohepatitis and hepatocellular carcinoma.
    Jacques S; Arjomand A; Perée H; Collins P; Mayer A; Lavergne A; Wéry M; Mni M; Hego A; Thuillier V; Becker G; Bahri MA; Plenevaux A; Di Valentin E; Oury C; Moutschen M; Delvenne P; Paquot N; Rahmouni S
    Sci Rep; 2021 Mar; 11(1):5817. PubMed ID: 33712680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
    Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
    Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.